ReviewInternational journal of nanomedicine2026
Nanomedicines Reshape the Tumor Microenvironment: Multidimensional Strategies from Modulating "Barriers" to Metabolic Intervention.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Emerging Nanoplatforms are Effective Against Tumor Hypoxia.International journal of nanomedicine · 2026Review
- The deubiquitinase USP35: from an oncogenic hub to a therapeutic target in human cancers.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoparticle-driven remodeling of the Tumor Microenvironment (TME) represents a transformative strategy in cancer therapy, shifting from traditional approaches to multidimensional modulation. This review explores how engineered nanoparticles precisely target and alter key TME components-including immune cells (eg, NK cells, dendritic cells, T cells), cancer-associated fibroblasts, and the extracellular matrix-to overcome "Chemical barriers" and "physical barriers". Furthermore, we highlight the pivotal role of nanoparticles in reprogramming TME metabolism, such as alleviating hypoxia, disrupting the Warburg effect, and modulating lipid and adenosine metabolism. By integrating immune activation with metabolic intervention, nanomedicines not only enhance anti-tumor immunity but also restore metabolic balance, offering a synergistic and potent therapeutic avenue for overcoming treatment resistance and inhibiting tumor progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.